Timothy Alexander

Toll Brothers Declares Dividend as Luxury Homebuilder Signals Stability FORT WASHINGTON, PA — Toll Brothers, Inc. (NYSE: TOL) said its board has approved a quarterly cash dividend of $0.25 per share, reinforcing the l […]

Madrigal Uses Equity Incentives to Lure Talent as MASH Drug Scales Up CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it granted equity inducement awards to four newly hired non-executive e […]

Donegal Declares Fresh Dividend as Insurer Stays Steady Amid Market Shifts MARIETTA, PA — Donegal Group Inc. (NASDAQ: DGICA) (NASDAQ: DGICB) said its board has approved a regular quarterly cash dividend, signaling b […]

Aprea Signals 2026 Inflection as Cancer Trials Advance and Cash Extends DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) told shareholders it is entering 2026 with advancing cancer programs, improving clinical s […]

Larimar Heads to JPMorgan as Rare Disease Program Draws Investor Attention BALA CYNWYD, PA — Larimar Therapeutics, Inc. (Nasdaq: LRMR) said members of its management team will present and hold one-on-one investor meetings at t […]

Axalta Reports Sharp Safety Gains and Emissions Cuts in New Sustainability Update PHILADELPHIA, PA — Axalta Coating Systems, Ltd. (NYSE: AXTA) released its 2023–2024 Sustainability Report, detailing progress on workplace safety, emi […]

Vishay Rolls Out Ultra-Fast Chip Fuses as Electronics Shrink and Power Densities Rise MALVERN, PA — Vishay Intertechnology, Inc. (NYSE: VSH) has expanded its circuit protection portfolio with two new thin-film chip fuse families aimed a […]

Bread & Soup Club Returns to The Buttery, Promising Cozy January Dinners MALVERN, PA — As winter settles in, The Buttery in Malvern is reviving a seasonal favorite designed to take the stress out of weeknight meals: its B […]

New COVID Pill Shows Promise Against Paxlovid in Early Head-to-Head Trial NEWTOWN, PA — Traws Pharma, Inc. (NASDAQ: TRAW) said interim results from a mid-stage clinical trial suggest its experimental COVID-19 treatment r […]

Fake Delivery Sites Explode Ahead of Holidays as Package Scams Surge As millions of Americans track holiday packages, cybercriminals are racing to exploit the season, driving a sharp spike in fake postal service websites […]

Law Firm Expands Construction Accident Support in North Philadelphia PHILADELPHIA, PA — The Weitz Firm, LLC said it has expanded its construction accident practice across North Philadelphia and Hunting Park, aiming to i […]

Annovis Sets Investor Webinar as Neurodegeneration Pipeline Reaches Inflection MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) said it will host a corporate update webinar later this month as the clinical-stage biotechnology c […]

White, Gray, Black Still Rule as Car Color Choices Shift Only at the Edges PHILADELPHIA, PA — Axalta (NYSE: AXTA) said neutral tones continued to dominate global vehicle color choices in 2025, with white, black, and gray a […]

NEXGEL Spin-Off Draws Strategic Capital as NexGelRx Sharpens Focus LANGHORNE, PA — NEXGEL, Inc. (NASDAQ: NXGL) said its planned spin-off, NexGelRx, has secured strategic investments from Eric Gruntfest and Ariel Imas o […]

FDA Fast Track Puts Palvella’s Rare Skin Drug on a Faster Regulatory Path WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) said the U.S. Food and Drug Administration has granted Fast Track designation to QTORIN™ rap […]

Madrigal Heads to JPMorgan as MASH Drug Puts Company in the Spotlight CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) said it will present at the J.P. Morgan Annual Healthcare Conference on Monday, J […]

Toll Brothers Opens $1M-Plus Luxury Community in Suburban Philadelphia ROYERSFORD, PA — Toll Brothers, Inc. (NYSE: TOL) has opened sales at Canterbury Meadows, a new luxury single-family home community in Montgomery C […]

CubeSmart Extends Dividend Growth Run With Fresh Quarterly Boost MALVERN, PA — CubeSmart (NYSE: CUBE) said its board has approved a quarterly dividend of $0.53 per common share, extending a long-running pattern of d […]

Medicus Fills Phase 2 Trial, Eyes FDA Talks for Needle-Free Skin Cancer PHILADELPHIA, PA — Medicus Pharma Ltd. (NASDAQ: MDCX) said it has completed U.S. enrollment for a Phase 2 clinical study testing a needle-free t […]

Rare Disease Breakthrough? Palvella Reports Strong Phase 2 Results WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) reported positive topline results from a mid-stage clinical trial that positions its lead drug c […]